Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Qiagen introduces novel assay for miRNA targets

QIAGEN : 08 May, 2007  (New Product)
A pioneering technology that creates a new dimension of capabilities for assays targeting microRNAs (miRNAs) has been introduced by Qiagen.
miRNA-related research in academia, pharma and molecular diagnostics can be considered one of the most rapidly evolving fields in today's life sciences. miRNAs are a newly discovered class of RNA molecules which have been found to play a significant role in the regulation of gene expression.

Recent discoveries indicate that miRNAs can correlate with cancer and other diseases, sparking significant interest in today's life science and molecular diagnostics research.

Despite the significant importance of this new class of RNA molecules, current methods for the isolation, identification and quantification of the presence of miRNA in biological samples are often cumbersome and imprecise.

Qiagen has unveiled a solution that allows for the sensitive, specific and simultaneous detection and quantification of hundreds of different miRNAs as well as other RNAs (mRNA).

The newly launched miScript product line incorporates a proprietary technology which for the first time enables researchers to identify multiple miRNAs from one single cDNA reaction in a given biological sample.

cDNA is a synthesised copy of the RNA which is widely used for PCR-based target detection in molecular biology, biomedical and pharmaceutical research.
The features offered by Qiagen's proprietary miScript Assay technology can equate to substantial time savings while allowing tremendous sensitivity and specificity.

'The new miRNA system marks a great step forward in miRNA research', said Dr Constanze Kindler, senior product manager at Qiagen.

'So far, researchers had to create a new copy of the DNA every time they wanted to detect a miRNA molecule'.

'This often leads to inconsistent results and a waste of precious samples, such as cancer and tissue cells'.

'miScript simply makes miRNA detection faster, more economical and convenient', Dr Kindler added.

The new system expands Qiagen's already broad portfolio of sample and Assay technologies targeting the rapidly expanding field of miRNA and demonstrates the company's well established capabilities and leadership in the field of sample and Assay technologies.

Together with Qiagen's other sample and Assay technologies products for miRNA such as with Qiagen's miRNeasy kits, the new Qiagen miScript system forms an integrated and comprehensive solution for the isolation and detection of miRNAs in hundreds of assays, which are available for the human, mouse and rat genome and which can easily be ordered via Qiagen's web portal GeneGlobe.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo